null

null

null

null

null

null

null

null

null

Minimal long-term debt; company is pre-revenue/early-revenue stage, relying on equity financing; 20% rate rise has negligible direct debt-service impact

Low direct sensitivity; primary risk is higher cost of future equity/debt raises and increased dilution pressure in a tight capital market

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-use hollow-fiber membrane cartridges sourced from limited biomedical suppliers; potential chokepoint in specialty polymer supply from Asia-Pacific

Minimal international revenue; no material sovereign currency devaluation exposure; regulatory approvals pending in key markets limit foreign revenue generation

Predominantly US-based revenues; negligible foreign currency exposure; EU and Japan represent aspirational markets with no current revenue contribution

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on specialized hollow-fiber membrane manufacturers; no single vendor publicly disclosed but substitutability is low given FDA device requirements

Medical device/therapeutic platform; cloud infrastructure is not a core operational dependency; clinical and manufacturing operations would be minimally disrupted

Grant-funded research and development with commercialization pathway; secondary revenue via licensing or partnership agreements

Low API coupling risk; proprietary hardware-based extracorporeal device platform with no significant third-party API dependencies in core product

Low Howey Test risk; revenue model based on medical device sales and grants, not investment contracts; no token or profit-sharing structure

Very High

Limited GDPR/CCPA exposure; patient data handled under HIPAA; clinical trial data subject to FDA regulations; EU patient data exposure minimal at current stage

Negligible antitrust risk; niche extracorporeal blood purification market with no dominant market position; competition from larger dialysis device makers

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Near-zero recurring revenue currently; predominantly grant/contract-based (~100% transactional/non-recurring); no subscription or multi-year commercial contracts disclosed

Primary monetization via medical device sales (Hemopurifier) and NIH/DoD grants; secondary via potential licensing of blood-purification IP

Device-plus-disposables model anticipated; pricing dependent on reimbursement codes not yet established; vulnerable to CMS/payer pushback on novel therapeutic pricing

Low current pricing power; no approved commercial product; future power contingent on FDA clearance and demonstrated clinical outcomes vs. standard of care

Target gross margin 50–65% at scale for medical device disposables; currently negative gross margin due to pre-commercial manufacturing costs

No free-rider leakage risk; proprietary single-use disposable device model requires repurchase; no open-source or freely replicable component pathway

Headcount-linear at current stage; R&D and clinical trial scaling requires proportional scientific and regulatory staff; limited operational leverage until commercialization

High marginal cost of growth pre-commercialization; each new clinical indication requires incremental trial spend, regulatory filing, and manufacturing scale-up

Not applicable; company does not operate a franchise model

At 10x scale, hospital/IDN procurement cycles and reimbursement infrastructure become binding constraints; CAC likely $50K–$200K per hospital account

No network effects present; medical device adoption driven by clinical evidence and physician training, not user-base scale

-112.9% Return on Assets (Negative equity)

Moderate recession resistance; targets life-threatening viral and oncology indications with limited elective-procedure exposure, but hospital budget cuts could delay adoption

Acute care hospitals and critical care units treating viral infectious diseases and cancer patients

US Department of Defense and NIH as grant/contract customers for biodefense and emerging pathogen applications

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital being consumed in clinical-stage R&D and regulatory pathway; no legacy infrastructure reallocation; future capex shift toward manufacturing scale-up post-approval

0000882291

AEMD